Increase in the incidence rate of conjunctival melanoma in Australia

News
Article

Investigators analysed the incidence and mortality rates from conjunctival melanoma cases over a 32-year period

A black background with a red line graph going down.  Image credit: ©Who is Danny – stock.adobe.com

The study's authors searched the Australian Cancer Database during the time frame 1982–2014 to identify cases of ocular melanoma. Image credit: ©Who is Danny – stock.adobe.com

The rate of conjunctival melanoma increased in Australia during the period from 1982 to 20141; however, the mortality rate remained the same, Australian researchers reported. Aaron B. Beasley, MD, from the School of Medical and Health Sciences, Edith Cowan University, and the Centre for Precision Health, Edith Cowan University, both in Joondalup, Western Australia, Australia, was the first author of the study.

Conjunctival melanoma is a rare form of mucosal melanoma and makes up around 5% to 7% of all ocular melanomas,2-4 the authors pointed out. However, considering that the incidence of ultraviolet-driven cutaneous melanoma increased over the past few decades,5 mostly as a result of improved recognition of in situ cases, the authors wanted to identify any changes in the incidence and mortality of conjunctival melanoma in Australia from 1982 to 2014.

The authors searched the Australian Cancer Database during the stated time frame to identify cases of ocular melanoma. The data from patients with conjunctival melanoma cases were extracted, and the incidence and mortality were analysed.

Dr Beasley and colleagues found that during the study period, 299 cases of conjunctival melanoma were identified. They reported that the age-standardised incidence rate was 0.48 (95% confidence interval [CI] = 0.41 to 0.54) per million per year. The incidence of conjunctival melanoma was higher in women than in men (0.52, 95% CI = 0.42 to 0.62 and 0.42, 95% CI = 0.33 to 0.51, respectively).

However, the incidence rates increased in both genders, ie, +1.46% in men and +1.41% in women (p = 0.023) during the study period.

The investigators reported the mean 5-, 10- and 15-year disease-specific survival rates were stable at 90%, 82%, and 80%, respectively, during the 33-year interval. Age, sex and state showed no significant differences.

Dr Beasley and colleagues concluded, “We found an increase in the rate of conjunctival melanoma diagnoses in Australia from 1982 to 2014. Over the same period, disease survival remained unchanged.”

References

  1. Beasley AB, Preen DB, McLenachan S, et al. Incidence and mortality of conjunctival melanoma in Australia (1982 to 2014). Invest Ophthalmol Vis Sci. 2023;64:2. doi: https://doi.org/10.1167/iovs.64.14.2
  2. Vajdic CM, Kricker A, Giblin M, et al. Incidence of ocular melanoma in Australia from 1990 to 1998. Int J Cancer. 2003;105:117–122.
  3. Isager P, Engholm G, Overgaard J, Storm H. Uveal and conjunctival malignant melanoma in Denmark 1943-97: observed and relative survival of patients followed through 2002. Ophthalmic Epidemiol. 2006;13:85–96.
  4. McLaughlin CC, Wu XC, Jemal A, et al. Incidence of noncutaneous melanomas in the U.S. Cancer. 2005;103:1000–1007.
  5. Aitken JF, Youlden DR, Baade PD, et al. Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995–2014. Int J Cancer. 2018;142:1528–1535.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.